Ask AI
ProCE Banner Series

Elevating CLL/SLL Management to Align Community Practice With Clinical Guidelines, Evidence-Based Data, and Shared Decisions

The live program is aimed at improving the treatment of patients with CLL/SLL through the integration of current NCCN guideline recommendations, clinical evidence that supports the use of novel targeted and cellular therapies, and sequencing strategies.

Complete the evaluation for this event: education.nccn.org/CLL-series

Who Should Attend

This activity is intended for oncologists, hematologists, physician associates (PAs), nurse practitioners (NPs), nurses, pharmacists, and other healthcare professionals who care for patients with CLL/SLL.

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact Customer Support prior to the live event.

CME/CE Info

Goal Statement
The goal of this activity is to improve learners’ knowledge, competence, and confidence to integrate therapies for CLL/SLL in clinical practice, including to appropriately sequence agents, individualize therapeutic regimens, and apply shared decision-making strategies (SDM) to optimize patient care outcomes.

Target Audience
This activity is intended for oncologists, hematologists, physician associates (PAs), nurse practitioners (NPs), nurses, pharmacists, and other healthcare professionals who care for patients with CLL/SLL.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Select first-line therapies for patients with treatment-naïve CLL/SLL considering available evidence, expert consensus and guideline recommendations, toxicity profiles, prognostic variables, comorbidities, duration of treatment (continuous vs. fixed duration), and patient preferences

  • Establish individualized treatment plans for patients with relapsed/refractory CLL/SLL based on optimal sequencing strategies recommended in the NCCN Guidelines (eg, assessment of response/intolerance to first-line therapy, testing for resistant mutations, and patient eligibility for treatment)  

  • Integrate newer therapeutic agents and regimens for the treatment of CLL/SLL in clinical practice in accordance with NCCN Guidelines and recent clinical trial data

  • Employ shared decision-making (SDM) strategies in clinical practice to foster treatment adherence and persistence, and optimize care outcomes in patients with CLL/SLL

Accreditation

Joint Accreditation Statement

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

NCCN designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development
NCCN designates this educational activity for a maximum of 1.0 contact hour. This program offers 1.0 pharmacotherapeutic contact hour for nurses. 

Continuing Pharmacy Education

NCCN designates this application-based continuing education activity for 1.0 contact hour (0.10 CEUs) of continuing education credit. UAN: JA4008196-0000-26-018-L01-P

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Physician Associate Continuing Medical Education

LogoDescription automatically generated

NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

American Board of Internal Medicine Maintenance of Certification

https://omni-channel-2022-assets-production.s3.amazonaws.com/editorupload/64a7123f4dc56.jpg 

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 medical knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregated participant data will be shared with the commercial supporters of this activity.

For ABIM MOC points, your information will be shared with the ABIM through NCCN's Joint Accreditation Program and Activity Reporting System (JA-PARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.

By sharing your Diplomate Board ID # and DOB, you are giving NCCN permission to use this information/data to report your participation to ABIM via the Joint Accreditation Program and Activity Reporting System (JA-PARS).

NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose all financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships. In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. Full disclosure of faculty relationships will be made prior to the activity. 

Acknowledgement

Provided by

Provided by the National Comprehensive Cancer Network (NCCN) in collaboration with Clinical Care Options, LLC dba Decera Clinical Education

NCCN

Supporters

Supported by educational grants from AstraZeneca and Lilly.

AstraZeneca

Lilly

Partners

Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

For customer support please click here.

Mailing Address:

 

Decera Clinical Education
12001 Sunrise Valley Drive
Suite 304
Reston, VA 20191